首页> 外文期刊>AIDS Research and Human Retroviruses >Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient.
【24h】

Emergence of an NNRTI resistance mutation Y181C in an HIV-infected NNRTI-naive patient.

机译:HIV感染的NNRTI天真患者中出现NNRTI抗药性突变Y181C。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The purpose of our study was to examine the emergence of the Y181C resistance mutation in an NNRTI-naive subject (index patient) at different time points. Phylogenetic trees in protease (PR) and partial reverse transcriptase (RT) regions were inferred by the maximum likelihood (ML) method. The Y181C mutation was detected for the first time when the patient was receiving d4T + ddI + LPV/r; the previous drug combination was 3TC + AZT + IDV. The particular mutation (Y181C) was not present at any time point during the treatment period with 3TC + AZT + IDV. Moreover, there was no evidence of resistance mutations in RT before the initiation of antiretroviral therapy. Phylogenetic analysis including sequences from the index patient and his spouse sampled at different time points, as well as control sequences belonging to the same HIV-1 subtype, revealed that there is no evidence of coinfection or reinfection with Y181C resistance strains, while the virus for both subjects was classified as subtype CRF14_BG. Overall, our findings suggest that the Y181C resistance mutation may be selected, not only by NNRTIs, but also by d4T. This may be of particular significance in developing countries where treatment with Triomune, a fixed combination of d4T, ddI, and nevirapine, is common. The genetic barrier against resistance of this combination may be lower than previously thought.
机译:我们研究的目的是检查在不同时间点的NNRTI天真受试者(索引患者)中Y181C耐药性突变的出现。通过最大似然法(ML)推断蛋白酶(PR)和部分逆转录酶(RT)区域的系统发生树。当患者接受d4T + ddI + LPV / r时首次检测到Y181C突变;先前的药物组合是3TC + AZT + IDV。在用3TC + AZT + IDV治疗期间的任何时间点都没有特定的突变(Y181C)。此外,在开始抗逆转录病毒治疗之前,没有证据显示RT中的耐药性突变。系统发育分析包括从索引患者及其配偶在不同时间点采样的序列以及属于同一HIV-1亚型的控制序列,发现没有证据表明Y181C耐药株可同时感染或再感染,而这两个受试者均被分类为CRF14_BG亚型。总体而言,我们的发现表明,不仅可以通过NNRTIs,还可以通过d4T选择Y181C耐药性突变。这在发展中国家普遍使用Triomune(d4T,ddI和nevirapine的固定组合)进行治疗的发展中国家尤其重要。抵抗这种组合的遗传障碍可能比以前认为的要低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号